United-Guardian (UG)
Market Price (12/23/2025): $6.13 | Market Cap: $28.2 MilSector: Consumer Staples | Industry: Household Products
United-Guardian (UG)
Market Price (12/23/2025): $6.13Market Cap: $28.2 MilSector: Consumer StaplesIndustry: Household Products
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 17%, Dividend Yield is 9.8%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 13%, FCF Yield is 5.5% | Weak multi-year price returns2Y Excs Rtn is -60%, 3Y Excs Rtn is -113% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -18%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -8.5%, Rev Chg QQuarterly Revenue Change % is -26% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% | Key risksUG key risks include [1] severe dependence on its sharply declining cosmetic ingredients segment, Show more. | |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21% | ||
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15% | ||
| Low stock price volatilityVol 12M is 37% | ||
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Advanced Materials, and Aging Population & Chronic Disease. Themes include Organic & Natural Products, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 17%, Dividend Yield is 9.8%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 13%, FCF Yield is 5.5% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -30% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Low stock price volatilityVol 12M is 37% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Advanced Materials, and Aging Population & Chronic Disease. Themes include Organic & Natural Products, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -60%, 3Y Excs Rtn is -113% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -18%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -8.5%, Rev Chg QQuarterly Revenue Change % is -26% |
| Key risksUG key risks include [1] severe dependence on its sharply declining cosmetic ingredients segment, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are the key points explaining the approximate -27.2% movement in United-Guardian (UG) stock from August 31, 2025, to December 19, 2025, when the stock closed at $6.09:1. Significant Decline in Q3 2025 Earnings: United-Guardian's latest earnings report on September 30, 2025, announced Q3 2025 earnings of $268.4k, marking a substantial 57.2% decrease from the previous quarter. The trailing 12-month earnings ending September 30, 2025, also showed a -43.4% year-over-year growth.
2. Persistent Long-Term Earnings and Profitability Decline: The company has experienced a consistent decline in earnings, with a 9.9% decrease per year over the past five years. Additionally, profit margins have narrowed to 19.5%, down from 28.3% in the prior year, indicating a deteriorating financial performance over a longer period.
Show more
Stock Movement Drivers
Fundamental Drivers
The -23.1% change in UG stock from 9/22/2025 to 12/22/2025 was primarily driven by a -17.3% change in the company's Net Income Margin (%).| 9222025 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 7.96 | 6.12 | -23.12% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 10.86 | 10.06 | -7.33% |
| Net Income Margin (%) | 23.55% | 19.48% | -17.29% |
| P/E Multiple | 14.30 | 14.35 | 0.31% |
| Shares Outstanding (Mil) | 4.59 | 4.59 | 0.00% |
| Cumulative Contribution | -23.12% |
Market Drivers
9/22/2025 to 12/22/2025| Return | Correlation | |
|---|---|---|
| UG | -23.1% | |
| Market (SPY) | 2.7% | 12.0% |
| Sector (XLP) | -0.1% | -15.3% |
Fundamental Drivers
The -23.4% change in UG stock from 6/23/2025 to 12/22/2025 was primarily driven by a -23.0% change in the company's Net Income Margin (%).| 6232025 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 7.99 | 6.12 | -23.42% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 11.41 | 10.06 | -11.81% |
| Net Income Margin (%) | 25.30% | 19.48% | -23.00% |
| P/E Multiple | 12.72 | 14.35 | 12.78% |
| Shares Outstanding (Mil) | 4.59 | 4.59 | 0.00% |
| Cumulative Contribution | -23.42% |
Market Drivers
6/23/2025 to 12/22/2025| Return | Correlation | |
|---|---|---|
| UG | -23.4% | |
| Market (SPY) | 14.4% | -1.6% |
| Sector (XLP) | -3.7% | -10.3% |
Fundamental Drivers
The -33.0% change in UG stock from 12/22/2024 to 12/22/2025 was primarily driven by a -31.2% change in the company's Net Income Margin (%).| 12222024 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 9.13 | 6.12 | -32.95% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 12.31 | 10.06 | -18.29% |
| Net Income Margin (%) | 28.30% | 19.48% | -31.17% |
| P/E Multiple | 12.04 | 14.35 | 19.20% |
| Shares Outstanding (Mil) | 4.59 | 4.59 | 0.00% |
| Cumulative Contribution | -32.95% |
Market Drivers
12/22/2024 to 12/22/2025| Return | Correlation | |
|---|---|---|
| UG | -33.0% | |
| Market (SPY) | 16.9% | 13.6% |
| Sector (XLP) | 0.0% | 0.2% |
Fundamental Drivers
The -35.5% change in UG stock from 12/23/2022 to 12/22/2025 was primarily driven by a -26.0% change in the company's Total Revenues ($ Mil).| 12232022 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 9.48 | 6.12 | -35.45% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 13.60 | 10.06 | -26.01% |
| Net Income Margin (%) | 22.11% | 19.48% | -11.90% |
| P/E Multiple | 14.49 | 14.35 | -0.98% |
| Shares Outstanding (Mil) | 4.59 | 4.59 | 0.00% |
| Cumulative Contribution | -35.45% |
Market Drivers
12/23/2023 to 12/22/2025| Return | Correlation | |
|---|---|---|
| UG | -11.9% | |
| Market (SPY) | 47.7% | 10.7% |
| Sector (XLP) | 14.6% | 2.3% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| UG Return | -23% | 22% | -33% | -30% | 41% | -32% | -59% |
| Peers Return | 8% | 34% | -19% | -7% | -3% | -5% | 0% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 113% |
Monthly Win Rates [3] | |||||||
| UG Win Rate | 42% | 50% | 50% | 42% | 58% | 42% | |
| Peers Win Rate | 58% | 72% | 45% | 50% | 47% | 48% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| UG Max Drawdown | -40% | -4% | -35% | -44% | 0% | -38% | |
| Peers Max Drawdown | -33% | -4% | -31% | -28% | -14% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: ASH, IFF, SCL, BCPC, SXT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/22/2025 (YTD)
How Low Can It Go
| Event | UG | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -77.4% | -25.4% |
| % Gain to Breakeven | 343.2% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -42.4% | -33.9% |
| % Gain to Breakeven | 73.5% | 51.3% |
| Time to Breakeven | 703 days | 148 days |
| 2018 Correction | ||
| % Loss | -26.0% | -19.8% |
| % Gain to Breakeven | 35.1% | 24.7% |
| Time to Breakeven | 22 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -59.9% | -56.8% |
| % Gain to Breakeven | 149.1% | 131.3% |
| Time to Breakeven | 641 days | 1,480 days |
Compare to IPAR, CENT, CL, KMB, CHD
In The Past
United-Guardian's stock fell -77.4% during the 2022 Inflation Shock from a high on 4/11/2022. A -77.4% loss requires a 343.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies for United-Guardian (UG):
- Corning, but focused on specialized lubricants and cosmetic ingredients instead of glass.
- A highly specialized 3M, concentrating on medical lubricants and cosmetic ingredients.
- The 'Intel Inside' for the personal care product and medical device industries.
AI Analysis | Feedback
- Cosmetic and Personal Care Ingredients: United-Guardian manufactures and supplies specialty ingredients for use in a wide range of beauty, skin care, hair care, and other personal care products.
- Health Care Products: This segment includes the prescription drug Renacidin, used for treating kidney stones, and specialty lubricants for medical devices.
- Specialty Industrial Products: The company produces various industrial lubricants, rust inhibitors, and other chemical additives for diverse industrial applications.
AI Analysis | Feedback
United-Guardian, Inc. (symbol: UG) primarily sells its products to other companies (Business-to-Business, B2B) rather than directly to individuals. The company manufactures and markets a diverse range of proprietary specialty industrial products, pharmaceuticals, cosmetic ingredients, and medical lubricants.
According to United-Guardian's financial filings (e.g., their most recent 10-K report), no single customer accounted for 10% or more of the company's sales in recent fiscal years. As such, United-Guardian does not publicly disclose the names of specific "major customers" because no individual customer meets the threshold for mandatory disclosure by the SEC.
However, based on its product lines, United-Guardian serves a broad base of customers across several industries. These customer categories represent who its customers are collectively:
- Pharmaceutical and Biotechnology Companies: These customers purchase Active Pharmaceutical Ingredients (APIs), finished dose pharmaceutical products, and specialized excipients for use in their own formulations.
- Cosmetic and Personal Care Product Manufacturers: Companies in this sector utilize United-Guardian's specialty ingredients, such as natural emollients, thickening agents, and other components, for creams, lotions, hair care products, and various other beauty and personal care items.
- Industrial and Medical Device Manufacturers, and Healthcare Distributors: This category encompasses companies that use United-Guardian's proprietary specialty lubricants (including the LUBRAJEL® brand) and release agents for industrial applications, or as components in medical devices, as well as distributors supplying these products to healthcare facilities.
AI Analysis | Feedback
null
AI Analysis | Feedback
Donna Vigilante, President
Donna Vigilante was appointed President of United-Guardian, Inc. in June 2023 and also joined the company's Board of Directors in May 2025. She has been with United-Guardian for over 20 years, having previously served as a Vice President and managed the Research and Development department. Ms. Vigilante has been responsible for the development of many of the company's products. She holds a Bachelor of Science degree in biochemistry with a minor in business from Stony Brook University and focuses on new marketing strategies and expanding product lines, particularly naturally-derived and environmentally friendly products.
Andrea J. Young, Chief Financial Officer, Controller, Treasurer & Secretary
Andrea J. Young serves as Chief Financial Officer, Controller, Treasurer, and Secretary, and also as Human Resources Manager for United-Guardian, Inc. She joined the company as CFO and Controller in September 2016. Ms. Young is a seasoned financial professional with extensive experience in accounting and financial management. Her previous roles include Assistant Controller at Utopia Home Care, Inc., Divisional Financial Controller at Graham Field Health Products, and former Audit Manager at Deloitte. Andrea Young holds a Master of Business Administration degree in Finance from Long Island University.
Peter A. Hiltunen, Senior Vice President, Production Manager
Peter A. Hiltunen holds the titles of Senior Vice President of Production & Procurement and Production Manager at United-Guardian, Inc. He possesses extensive experience in overseeing the company's manufacturing operations and supply chain. Mr. Hiltunen is crucial in ensuring the efficient and cost-effective production of United-Guardian's product portfolio, with responsibilities including managing raw material sourcing, inventory control, production scheduling, quality assurance, and overall operational efficiency.
Denise Costrini, Marketing Director
Denise Costrini is the Marketing Director at United-Guardian, Inc. In this role, she is responsible for developing and executing the company's marketing strategies to promote its products and enhance brand awareness. Her responsibilities encompass market research, advertising, public relations, digital marketing, and brand management, playing a vital role in understanding customer needs and market trends.
AI Analysis | Feedback
The key risks to United-Guardian's business include:
-
High Dependence on Volatile Cosmetic Ingredients Segment and Intense Competition/Tariffs: United-Guardian's earnings have been significantly impacted by a sharp decline in its cosmetic ingredients sales, a primary revenue driver. This segment faces substantial headwinds from increased competition, particularly from cheaper Asian producers, and U.S. tariffs on Chinese imports, leading to supply chain disruptions and excess inventory. The company experienced a 63% plunge in cosmetic ingredients sales in Q1 2025, contributing to an overall 24% revenue decline.
-
Significant Reliance on a Single Pharmaceutical Product (Renacidin®): The company's pharmaceutical segment, primarily driven by its flagship drug Renacidin®, represents a substantial portion of its revenue, making it a "single-point failure" risk. While Renacidin sales have shown some growth, the heavy reliance on this one product exposes the company to risks associated with supply chain issues, regulatory changes, or increased competition in its niche market.
-
Unsustainable Dividend Payout Ratio Amidst Declining Profitability: United-Guardian's dividend policy is a critical vulnerability, with a payout ratio that has reached 111.1%. This means the company is distributing more in dividends than it earns, indicating an unsustainable model that is being funded by retained earnings or reserves rather than current profits. This unsustainable payout ratio is exacerbated by plummeting earnings and a challenging operating environment characterized by declining net profit, reduced net sales, and lower operating cash flow.
AI Analysis | Feedback
nullAI Analysis | Feedback
United-Guardian (UG) operates primarily in the personal care, pharmaceutical, and industrial sectors, manufacturing and marketing proprietary ingredients and finished products. The addressable market sizes for its main product categories are as follows:
- Personal Care Ingredients: The global personal care ingredients market was valued at approximately USD 13.45 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 4.6% during the forecast period. Other estimates place the global market size at USD 11.83 billion in 2024, expected to reach USD 16.22 billion by 2030 with a CAGR of 5.47%. Another report indicates a global market size of USD 15.48 billion in 2025, predicted to increase to about USD 25.96 billion by 2034, growing at a CAGR of 5.92%.
- Pharmaceuticals (Active Pharmaceutical Ingredients - API): The global active pharmaceutical ingredients market size was estimated at USD 255.0 billion in 2024 and is projected to reach USD 359.45 billion by 2030, growing at a CAGR of 5.8% from 2025 to 2030. Another assessment values the global API market at USD 136.22 billion in 2024, with a projection to reach USD 198.39 billion by 2030 at a 6.6% CAGR.
- Medical Lubricants: null
- Specialty Industrial Products: null
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for United-Guardian (UG) over the next 2-3 years:
- Expanded Formulary Access for Renacidin: United-Guardian is actively working with an external pharmaceutical consultant to secure placement of Renacidin, its most significant pharmaceutical product, on additional drug formularies. This initiative is expected to significantly increase sales of Renacidin in the coming years.
- Strategic Expansion in Sexual Wellness Ingredients: The company has implemented strategic distribution arrangements, including a partnership with Brenntag Specialties in late 2023 for a new line of sexual wellness ingredients across the United States and various international markets. Additionally, United-Guardian has broadened its collaboration with Azelis Group in Europe and is extending its distributor network to include South Korea for certain products, aiming to diversify revenue and expand its geographic footprint.
- Consistent Growth in Medical Lubricants: The medical lubricants segment has demonstrated steady growth, with sales increasing by 6% in the first nine months of 2025 and 16% in fiscal year 2024. This consistent performance is anticipated to continue contributing to future revenue.
- Recovery and Market Share Gains in Cosmetic Ingredients: Despite recent declines attributed to inventory adjustments by a major distributor, management is focused on efforts to restore competitiveness and regain market share in Asia through expanded distribution. The anticipated launch of the new Natrajel line in 2026 is also expected to support the stabilization and growth of cosmetic ingredient sales.
AI Analysis | Feedback
Capital Expenditures
- United-Guardian's investing cash flow, which includes capital expenditures, was -$468,680 in 2020, -$183,470 in 2021, $897,560 in 2022, $4,730,000 in 2023, and -$7,080,000 in 2024.
- In 2024, a significant portion of the net cash used in investing activities, amounting to $7,077,395, was primarily attributed to increased investment in marketable securities.
- The company had plans for capital expenditures by the end of 2024, including upgrading its building sprinkler system and replacing the roof on its facility in Hauppauge, NY.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| United-Guardian Earnings Notes | ||
| With United-Guardian Stock Sliding, Have You Assessed The Risk? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to UG. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11302025 | BF-B | Brown-Forman | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -2.3% | -2.3% | -2.3% |
| 11302025 | CPB | Campbell's | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -6.3% | -6.3% | -7.5% |
| 11212025 | ENR | Energizer | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.1% | 10.1% | -5.3% |
| 11212025 | FLO | Flowers Foods | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -1.6% |
| 11142025 | CLX | Clorox | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -5.4% | -5.4% | -5.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for United-Guardian
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 63.02 |
| Mkt Cap | 3.3 |
| Rev LTM | 1,710 |
| Op Inc LTM | 146 |
| FCF LTM | 28 |
| FCF 3Y Avg | 86 |
| CFO LTM | 130 |
| CFO 3Y Avg | 178 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.6% |
| Rev Chg 3Y Avg | -4.9% |
| Rev Chg Q | -1.5% |
| QoQ Delta Rev Chg LTM | -0.4% |
| Op Mgn LTM | 10.6% |
| Op Mgn 3Y Avg | 9.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 7.5% |
| CFO/Rev 3Y Avg | 10.7% |
| FCF/Rev LTM | 2.3% |
| FCF/Rev 3Y Avg | 5.2% |
Price Behavior
| Market Price | $6.12 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/17/1992 | |
| Distance from 52W High | -43.7% | |
| 50 Days | 200 Days | |
| DMA Price | $6.50 | $7.79 |
| DMA Trend | down | down |
| Distance from DMA | -5.9% | -21.4% |
| 3M | 1YR | |
| Volatility | 33.1% | 37.5% |
| Downside Capture | 106.51 | 24.67 |
| Upside Capture | -34.99 | -18.28 |
| Correlation (SPY) | 11.4% | 13.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.51 | 0.32 | 0.27 | -0.01 | 0.28 | 0.27 |
| Up Beta | 0.58 | -0.37 | -0.66 | -0.04 | 0.43 | 0.06 |
| Down Beta | 0.58 | 0.45 | 0.27 | 0.24 | 0.32 | 0.18 |
| Up Capture | -133% | -70% | -52% | -40% | -9% | 8% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 4 | 12 | 22 | 55 | 113 | 362 |
| Down Capture | 158% | 134% | 146% | 44% | 45% | 82% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 16 | 28 | 39 | 68 | 129 | 369 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of UG With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| UG | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -34.2% | -1.8% | 14.7% | 67.3% | 6.8% | -0.5% | -16.6% |
| Annualized Volatility | 37.3% | 13.9% | 19.7% | 19.3% | 15.2% | 17.6% | 35.4% |
| Sharpe Ratio | -1.05 | -0.37 | 0.57 | 2.54 | 0.23 | -0.18 | -0.25 |
| Correlation With Other Assets | 0.7% | 14.0% | 9.0% | 10.1% | 10.1% | 5.1% | |
ETFs used for asset classes: Sector ETF = XLP, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of UG With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| UG | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -11.5% | 5.8% | 15.0% | 18.9% | 11.8% | 5.1% | 35.8% |
| Annualized Volatility | 46.0% | 13.0% | 17.1% | 15.5% | 18.7% | 18.9% | 48.9% |
| Sharpe Ratio | -0.11 | 0.24 | 0.71 | 0.98 | 0.51 | 0.18 | 0.63 |
| Correlation With Other Assets | 8.1% | 8.7% | 2.1% | 0.1% | 8.3% | 1.7% | |
ETFs used for asset classes: Sector ETF = XLP, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of UG With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| UG | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -5.9% | 7.4% | 14.9% | 14.9% | 6.7% | 5.5% | 69.9% |
| Annualized Volatility | 41.9% | 14.7% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.00 | 0.38 | 0.71 | 0.84 | 0.30 | 0.23 | 0.90 |
| Correlation With Other Assets | 14.0% | 14.4% | 0.9% | 3.6% | 14.4% | 6.3% | |
ETFs used for asset classes: Sector ETF = XLP, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | -6.3% | -12.3% | -15.9% |
| 8/8/2025 | -0.5% | -1.0% | 6.4% |
| 3/21/2025 | -3.0% | -7.2% | -13.9% |
| 11/8/2024 | -12.1% | -19.3% | -19.2% |
| 8/9/2024 | -2.0% | 7.4% | 23.5% |
| 3/22/2024 | 6.1% | 0.9% | 7.3% |
| 11/6/2023 | 27.8% | 22.5% | 36.3% |
| 8/11/2023 | -0.7% | -2.1% | -1.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 9 |
| # Negative | 10 | 10 | 9 |
| Median Positive | 5.3% | 6.4% | 12.7% |
| Median Negative | -3.7% | -5.5% | -11.0% |
| Max Positive | 27.8% | 22.5% | 36.3% |
| Max Negative | -12.9% | -19.3% | -21.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11062025 | 10-Q 9/30/2025 |
| 6302025 | 8082025 | 10-Q 6/30/2025 |
| 3312025 | 5132025 | 10-Q 3/31/2025 |
| 12312024 | 3212025 | 10-K 12/31/2024 |
| 9302024 | 11122024 | 10-Q 9/30/2024 |
| 6302024 | 8122024 | 10-Q 6/30/2024 |
| 3312024 | 5132024 | 10-Q 3/31/2024 |
| 12312023 | 3222024 | 10-K 12/31/2023 |
| 9302023 | 11132023 | 10-Q 9/30/2023 |
| 6302023 | 8112023 | 10-Q 6/30/2023 |
| 3312023 | 5122023 | 10-Q 3/31/2023 |
| 12312022 | 3232023 | 10-K 12/31/2022 |
| 9302022 | 11092022 | 10-Q 9/30/2022 |
| 6302022 | 8122022 | 10-Q 6/30/2022 |
| 3312022 | 5132022 | 10-Q 3/31/2022 |
| 12312021 | 3232022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.